The recently launched digital health service allows patients to schedule sample collection for laboratory tests at their homes or offices.
Laboratories of all kinds are automating their workflows, particularly those involving sample prep and other preanalytical steps.
The proposed change would delete payable cancer codes if they contain the word "unspecified" even if the word is included in a code that doesn't impact coverage.
By guiding light through tunnels on a fluidic chip, users can see individual molecules, including DNA, RNA, and proteins.
The instrument, which is undergoing the FDA clearance process, has the capability to do PCR testing, clinical chemistry, and immunoassays.
Under the program, accredited laboratories can perform premarket testing for medical device companies before the companies undergo formal FDA submission.
The company is working to transition its instruments sold in the US from COVID-19 testing to sepsis testing and increase its installed base.
The firm will submit its SARS-CoV-2 test and Talis One instrument to the US Food and Drug Administration for Emergency Use Authorization in the second quarter.
The Danaher subsidiary's core revenues grew more than 90 percent in the first quarter of 2021 and it expects to ship 45 million SARS-CoV-2 tests for the year.
During the company's first quarter earnings call, CEO Robert Ford noted that its COVID-19 testing-related sales were driven by rapid, point-of-care testing.